Lilly Sets Date for 2013 Diabetes Pipeline Update to the Media and Investment Community

Lilly Sets Date for 2013 Diabetes Pipeline Update to the Media and Investment
                                  Community

PR Newswire

INDIANAPOLIS, March 5, 2013

INDIANAPOLIS, March 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
will conduct a conference call for the media and investment community to
provide a pipeline update for itsdiabetes business on Monday, June 24, 2013.
The call, which is being held in conjunction with the 73^rd American Diabetes
Association Scientific Sessions, will include updates on Phase III data for
empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2)
inhibitor, and dulaglutide, an investigational once-weekly glucagon-like
peptide-1 (GLP-1) receptor agonist. Empagliflozin is in development in
partnership with Boehringer Ingelheim.

The conference call will be held from 7 p.m. to 8:30 p.m. US Central Time
(CDT). Investors, media and the general public can access a live webcast of
the conference call through a link that will be posted on Lilly's website at
www.lilly.com. The webcast of the conference call will be available for replay
through July 24, 2013.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, IN, Lilly provides answers –
through medicines and information – for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world's first commercial insulin. Today we work to meet the diverse needs
of people with diabetes through research and collaboration, a broad and
growing product portfolio and a continued commitment to providing real
solutions—from medicines to support programs and more—to make lives better.
For more information, visit www.lillydiabetes.com.

P-LLY

Refer to: (317) 701-4007 – Kelley Murphy (media)
          (317) 655-6874 – Philip Johnson (investors)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20111111/DE03493LOGO )

SOURCE Eli Lilly and Company

Website: http://www.lilly.com